| |
Subscription-based business models are vital for successful direct-to-consumer (DTC) testing. Discover the ins and outs of DTC testing and how to outlast the competition in this free guide. Download Now.
|
|
Today's Big NewsJan 13, 2023 |
|
March 14-15, 2023 | San Francisco, CA Gain valuable insight from cross-functional team members responsible for search and evaluation, legal/IP, portfolio management, strategic alliances, business development and licensing. Register today to secure our lowest rates!
|
|
| By Max Bayer TCR² Therapeutics appeared to become the latest biotech to make major staff reductions last week as it laid out its clinical and corporate vision for the new year. But Fierce Biotech can reveal that it was in fact the second round of layoffs at the company in less than six months, after TCR² quietly removed a fifth of its staff in August. |
|
|
|
By Ben Adams It’s been a long, bumpy road for Geron and its experimental blood cancer asset imetelstat, but, as the biotech hopes to finally be nearing the finish line, it is hiring a bunch of new commercial leads to help bring home the sales. |
By Helen Floersh The Wellcome-funded project will see a new test developed that can detect multi-pathogen co-infections in a single swab. |
Sponsored by Personalis Advanced ctDNA analysis yields biomarkers of cancer dynamics essential in therapeutic monitoring & intervention. Learn how NeXT Personal® detects MRD, monitors variants, & delivers powerful insights. |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
By Nick Paul Taylor New Biogen CEO Chris Viehbacher has set out plans for a subcutaneous version of lecanemab, outlining how changing the delivery method of the Eisai-partnered Alzheimer’s disease drug could be particularly valuable for pre-symptomatic patients. |
By Conor Hale Illumina could well be facing the maximum fine the European Commission can impose, totaling up to 10% of its annual revenues, over the DNA sequencing giant’s premature acquisition of the blood testing company Grail, according to a report from Reuters. |
By Nick Paul Taylor Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. |
By Conor Hale In an email to employees that was also published by the company as a blog post, CEO Stephen Gillett said Verily would no longer pursue multiple lines of business. |
By Sharon Klahr Coey Pfizer’s new COVID-19 booster ad starring Martha Stewart is both odd and weirdly compelling to watch. |
By Max Bayer,Gabrielle Masson Novavax CEO Erck to retire after 12 years and overseeing COVID vaccine development. CureVac CEO steps aside after getting lapped in the COVID vaccine race. Nkarta promotes Shook to chief medical officer role. |
By Angus Liu Eisai and Biogen's Alzheimer's disease drug kicks off high-stake launch with an expected FDA approval. Astellas inked two deals in rare disease and antibody research to kick off 2023. Samsung Biologics plans to start making antibody-drug conjugates at its plant in early 2024, CEO said. And more. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the FDA's shifting stance on cancer drug approvals. Plus, we cover the annual JPM week and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 1:00pm ET This session will discuss key 2023 trends for healthcare and life sciences and how organizations should think about their data strategy and interoperability as they navigate the winds of change. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
